Introduction
Review
Disability weights - design choices
Literature review - selection criteria and definitions
Literature review - data sources and search strategy
Literature review - data extraction
Comparison of disability weights
Results
Year | Study | Ref no. | Region | Multiple or single cause? | Panel composition | N panel | N health states | Health state description | Time presentation | Valuation methods(% of total number of health states valued by each of the methods)
|
---|---|---|---|---|---|---|---|---|---|---|
1996 | Murray et al. | [25] | Global | M | ME | 10 | 483 | DS | PP | <1% PTO, 99% VAS |
1997 | Stouthard et al. | [19] | Netherlands | M | ME | 38 | 175 | DS + EQ-5D | PP & AP | 10% PTO, 90% VAS |
1999 | Üstün et al. | [26] | Global | M | HP, PM, PT, PX | 241 | 17 | DS | PP | 100% ranking |
2000 | Havelaar et al. | [29] | Netherlands | M | ME | 35 | NA | NA | PP | Interpolation |
2000 | Jelsma et al. | [30] | Zimbabwe | M | PP, ME | 68 | 22 | NA | PP | VAS (ranking) |
2000 | Mathers et al. | [31] | Australia | M | Model | - | Model | MAUI (EQ-6D) + DDW | PP | EQ-6D: Not applicable |
2002 | Baltussen et al. | [32] | Burkina Faso | M | PP, HP | 56 | 9 | DS (scenarios) | PP | Adapted VAS/interpolation |
2003 | Schwarzinger et al. | [33] | Europe | M | ME, NHP | 232 | 15 | DS + EQ-5D | PP | 100% VAS, 60% TTO, 60% PTO |
2004 | Brennan et al. | [34] | Australia | S (oral) | Model | - | 18 | MAUI (EQ-5D) | PP | EQ-6D: Not applicable |
2005 | Kruijshaar et al. | [35] | Netherlands | M | ME | 49 | 9 | DS + EQ-5D | PP | 100% interpolation |
2007 | Brennan et al. | [36] | Australia | S (oral) | Model | - | 6 | MAUI (EQ-5D) | PP | EQ-6D: not applicable |
2007 | Yoon et al. | [37] | Korea | M | ME | 30 | 123 | NA | PP | 13% PTO, 87% interpolation |
2008 | Basiri et al. | [38] | Iran | S (urologic) | ME | 10 | 76 | NA | PP | 100% interpolation |
2008 | Haagsma et al. | [20] | Netherlands | S (injury) | PP | 143 | 44 | DS + EQ-5D | AP | 100% VAS, 100% TTO |
2008 | Haagsma et al. | [39] | Netherlands | M | PP | 107 | 39 | DS + EQ-5D | AP | 100% VAS, 100% PTO |
2009 | Haagsma et al. | [23] | Netherlands | S (injury) | Model | - | 7 | MAUI (EQ-5D) | PP | EQ-5D: not applicable |
2009 | Hong et al. | [28] | US/Southeast Asia | S (stroke) | ME | 9 | 5 | NA | NA | 100% PTO |
2009 | Lai et al. | [40] | Estonia | M | ME | 25 | 283 | DS | PP | 9% PTO, 91% VAS |
2010 | Kwong et al. | [41] | Canada | M | Model | - | Model | MAUI (CLAMES) | PP | CLAMES: not applicable |
2011 | Lyons et al. | [42] | UK | S (injury) | Model | - | 13 | MAUI (EQ-5D) | PP | EQ-5D: not applicable |
2012 | Salomon et al. | [27] | Global | M | PP | 30230 | 220 | DS (without label) | PP | 100% Paired comparison |
2011 | Van Spijker et al. | [43] | Netherlands | M | ME | 16 | 12 | DS + EQ-5D | PP | 100% VAS |
Methodological design choices to render the disability weights
Health state description
Time presentation
Panel composition
Valuation method
Experimental design
Comparison of disability weights
Author(s) of the study | Chronic sequelae of CVA/stroke | Paraplegia | Dental caries | Rheumatoid arthritis | Diabetes | Depression | Gastro-enteritis | Acute cystitis | |
---|---|---|---|---|---|---|---|---|---|
[25] | Murray et al., 1996 | Untreated 0.282 (varies with age between 0.262 - 0.301); treated 0.241 (varies with age between 0.224-0.258) | 0.725 | 0.081 | Untreated 0.233, treated 0.174 | Treated 0.012; untreated 0.033 | Treated 0.302; Untreated 0.600 | 0.105 (varies with age between 0.086 - 0.119) | - |
Stouthard et al., 1997 | Mild impairments 0.36 (CI 0.23- 0.49); Moderate impairments 0.63 (CI 0.543-0.718); Severe impairments 0.92 (CI 0.853-0.994) | 0.57 (CI 0.489-0.651) | 0.01 (CI 0.001-0.009) | Mild 0.21 (CI 0.127-0.303); moderate 0.37 (CI 0.219-0.515); severe 0.94 (CI 0.92-0.961) | Uncomplicated 0.07 (CI 0.047-0.094; with neuropathy 0.19 (CI 0.126-0.255); with nephropathy 0.29 (CI 0.201-0.38) | Mild 0.14 (CI 0.086-0.194); moderate 0.35 (CI 0.272-0.425); severe 0.76 (CI 0.556-0.971); severe with psychotic features 0.83 (CI 0.748-0.916) | Uncomplicated course 0.01 (CI 0.001-0.009); complicated course 0.03 (CI 0.018-0.039) | 0.01 (CI 0-0.039) | |
[26] | Üstün et al., 1999 | - | r | - | r | r | - | - | |
[29] | Havelaar et al., 2000 | - | - | - | - | - | Severe gastroenteritis 0.393 (CI 0.049-0.821) | ||
[30] | Jelsma et al., 2000 | - | r | - | r | - | r | - | - |
Mathers et al., 2000 | - | - | Episode resulting in tooth loss 0.014 | - | - | - | - | - | |
[32] | Baltussen et al., 2002 | - | PP: 0.42; HP: 0.55 | - | - | PP: 0.49; HP: 0.34 | PP: 0.74; HP: 0.66 | - | |
[33] | Schwarzinger et al., 2003 | Moderate impairments 0.68 | - | - | - | Uncomplicated 0.34 | Severe 0.78 | - | |
[34] | Brennan et al., 2004 | - | - | 0.044 (0.013-0.076) | - | - | - | - | - |
[35] | Kruijshaar et al., 2005 | - | - | - | Mild 0.19 (CI 0.16-0.22); moderate 0.51 (CI 0.46-0.55); severe 0.84 (0.80-0.88) | - | |||
[36] | Brennan et al., 2007 | - | - | - | - | - | - | - | - |
[37] | Yoon et al., 2007 | NA | NA | NA | NA | NA | NA | NA | NA |
[38] | Basiri et al., 2008 | - | - | - | - | - | - | - | 0.018 (-0.047-0.083) |
[20] | Haagsma et al., 2008 | - | Acute 0.563 (0.495-0.631), stable 0.656 (0.525-0.786) | - | - | - | - | - | - |
[39] | Haagsma et al., 2008 | - | 0.551 (0.36-0.74) | - | - | - | - | - | - |
[23] | Haagsma et al., 2009 | - | - | - | - | - | - | Mild 0.010 (-0.005-0.025), moderate 0.015 (0.005-0.025), severe 0.041 (0.014-0.067) | - |
[28] | Hong et al., 2010 | mRS1 0.046 (CI 0.004-0.088); mRS2 0.212 (0.175-0.250); mRS3 0.331 (0.292-0.371); mRS4 0.652 (0.625-0.678); mRS5 0.944 (0.873-1.015) | - | - | - | - | - | - | - |
[40] | Lai et al., 2009 | 0.547 | 0.669 | 0.078 | 0.203 | Insulin dependent 0.264, insulin non-dependent 0.029 | 0.147 | 0.011 | |
Kwong et al., 2010 | - | - | - | Active episode 0.262; chronic active 0.058; advanced damage 0.465 | - | Mild 0.122; moderate 0.440; severe 0.558 | Mild 0.023; moderate 0.041; severe 0.086 | 0.023 | |
[42] | Lyons et al., 2011 | - | - | - | - | - | - | - | - |
[27] | Salomon et al., 2012 | mild: 0.021 (0.011-0.037) | untreated 0.440 (CI 0.290-0.588), treated | Symptomatic: 0.012 (0.005-0.023) | Legs, mild: 0.023 (0.013-0.039) | - | Mild: 0.159 (UI 0.107-0.223) | Mild: 0.061(0.036-0.093) | - |
moderate: 0.076 (0.050-0.110) | |||||||||
0.047 (CI 0.029-0.072) | Legs, moderate: 0.079 (0.053-0.115) | Moderate: 0.406 (UI 0.276-0.551) | Moderate: 0.202 (0.133-0.299) | ||||||
moderate plus cognition problems: 0.312 (0.211-0.433) | |||||||||
Legs, severe: 0.171 (0.117-0.240) | Severe: 0.655 (UI 0.469-0.816) | Severe: 0.281 (0.184-0.399) | |||||||
severe: 0.539 (0.363-0.705) | |||||||||
Arms, mild: 0.024 (0.014-0.041) | |||||||||
Arms, moderate: 0.114 (0.077-0.159) | |||||||||
Arms, severe: 0.292 (0.077-0.159) | |||||||||
Generalised, moderate: 0.292 (0.197-0.410) | |||||||||
Generalised severe: 0.606 (0.42-0.77) | |||||||||
severe plus cognitive problems: 0.567 (0.394-0.738) | |||||||||
[43] | Van Spijker et al., 2011 | - | - | - | 0.33 (CI 0.05-0.61) | - | Severe with psychotic features 0.74 (CI 0.40-1.08) | - | - |
Ref nr.
|
Author(s) of the study
|
Severe anemia
|
Infertility
|
Below the knee amputation
|
Deafness
|
Mild mental retardation
|
Dementia
|
Blindness
| |
[25] | Murray et al., 1996 | 0.087-0.093 (varies with age) | 0.180 | 0.3 | Untreated 0.213-0.233; treated 0.168-0.175 | Untreated 0.469-0.485; treated 0.394-0.468 | Untreated 0.600; treated 0.302 | Untreated 0.600; treated 0.488-0.493 | |
Stouthard et al.,1997 | 0.11 (CI 0.03-0.20) | Childhood 0.23 (0.12-0.33); elderly 0.37 (0.34-0.41) | 0.29 (CI 0.09-0.50) | Mild 0.27 (CI 0.13-0.42); moderate 0.63 (CI 0.41-0.86); severe 0.94 (CI 0.93-0.95) | 0.43 (CI 0.34-0.52) | ||||
[26] | Üstün et al., 1999 | r | r | r | r | r | r | r | |
[29] | Havelaar et al., 2000 | - | - | - | - | - | - | - | |
[30] | Jelsma et al., 2000 | r | r | r | r | r | r | r | |
Mathers et al., 2000 | - | - | - | - | - | - | |||
[32] | Baltussen et al., 2002 | - | - | - | PP: 0.16; HP: 0.11 | - | - | PP 0.35; HP 0.36 | |
[33] | Schwarzinger et al., 2003 | - | - | - | - | - | Mild dementia 0.46 | - | |
[34] | Brennan et al., 2004 | - | - | - | - | - | - | - | |
[35] | Kruijshaar et al., 2005 | - | - | - | - | - | - | - | |
[36] | Brennan et al., 2007 | - | - | - | - | - | - | - | |
[37] | Yoon et al., 2007 | NA | NA | NA | NA | NA | NA | NA | |
[38] | Basiri et al., 2008 | - | - | - | - | - | - | - | |
[20] | Haagsma et al., 2008 | - | - | - | - | - | - | - | |
[39] | Haagsma et al., 2008 | - | - | - | - | - | - | - | |
[23] | Haagsma et al., 2009 | - | - | - | - | - | - | - | |
[28] | Hong et al., 2010 | - | - | - | - | - | - | - | |
[40] | Lai et al., 2009 | 0.168 | 0.547 | 0.747 | 0.254 | 0.242 | 0.261 | 0.478 | |
Kwong et al., 2010 | - | 0.122 | Diabetic retinopathy 0.248 | ||||||
[42] | Lyons et al., 2011 | - | - | - | - | - | - | - | |
[27] | Salomon et al., 2012 | 0.164 (UI 0.112-0.228) | Primary 0.011 (UI 0.005-0.021); secondary 0.006 (UI 0.002-0.013) | Untreated 0.164 (UI 0.111-0.229); treated 0.021 (UI 0.011-0.035) | Complete 0.033 (UI 0.020-0.052); complete with ringing 0.092 (UI 0.061-0.134) | 0.031 (UI 0.018-0.049) | Mild 0.082 (CI 0.055-0.117); moderate 0.346 (CI 0.233-0.475); severe 0.438 (CI 0.299-0.584) | 0.195 (0.132-0.272) | |
[43] | Van Spijker et al., 2011 | - | - | - | - | - | - | - |
Murray et al., 1996 | Stouthard et al., 1997 | Lai et al., 2009 | Salomon et al., 2013 | |
---|---|---|---|---|
Murray et al., 1996 | X | 0.462* | 0.626** | 0.351 |
Stouthard et al., 1997 | X | 0.534* | 0.107 | |
Lai et al., 2009 | X | 0.515* | ||
Salomon et al., 2013 | X |